Objective: Menopause is associated with critical changes in the cardiovascular system, and the possible effect of hormonal replacement therapy (HRT) on these changes is under investigation. The aim of our study was to evaluate in postmenopausal women the effects of HRT and clonidine on the response of plasma calcitonin gene-related peptide (CGRP) and plasma atrial natriuretic peptide (ANP) to the upright posture test and the saline infusion test respectively. Methods: CGRP and ANP levels were measured with specific radioimmunological assays and expressed in pmol/l (meansϮS.E.M). Design: Postmenopausal women (age 46-53 years) (n=18) were studied before and after 3 months of HRT (n=13) or clonidine treatment (n=5). Results: After HRT or clonidine treatment plasma CGRP levels (14·9Ϯ1·6 and 15·9Ϯ3·8 pmol/l) were significantly higher than before (9·8Ϯ0·6 and 10·5Ϯ1·6 pmol/l) (P<0·01). The assumption of upright posture caused no change in plasma CGRP levels before treatment, while after HRT, but not after clonidine treatment, an increase in plasma CGRP levels was observed (P<0·01 at 5 and 20 min). Basal plasma ANP levels significantly decreased after both HRT and clonidine treatment (P<0·01). In untreated women the saline infusion test did not induce any change in plasma ANP levels; a significant response to the test was restored after HRT but not after clonidine treatment (P<0·01 at 90 and 120 min).
Introduction
In the last two decades numerous peptides involved in the regulation of cardiovascular activity have been identified, such as endothelin, neuropeptide Y, angiotensin II, atrial natriuretic peptide (ANP) and calcitonin gene-related peptide (CGRP). Studies on both humans and animals have shown that some of these peptides are measurable in the plasma.
CGRP is a 37 amino acid neuropeptide produced by central and peripheral nervous systems and also expressed in the heart, blood vessels, pituitary, thyroid, lung and gastrointestinal tract (1, 2) . In particular, CGRP is localized in smooth muscle cells of blood vessels and in perivascular nerves. CGRP has a potent cardiovascular effect, inducing a positive chronotropic and inotropic effect (3, 4) . The mechanism by which CGRP is involved in the regulation of vascular tone is unclear, even though interaction with the reninangiotensin system as well as with cholinergic and adrenergic systems has been demonstrated (5, 6) . CGRP is measurable in systemic circulation, and the assumption of an upright position provokes a rapid significant increase in plasma CGRP levels (7) . Pathological conditions associated with a rise in plasma CGRP levels are cirrhosis and congestive heart failure (8, 9) .
ANP is produced by cardiac myocytes and released into the circulation primarily in response to atrial stretch and volume expansion (10) . It is a hormone involved in the maintenance of fluid and salt homoeostasis, inducing natriuresis and vasodilation and inhibiting the renin-angiotensin-aldosterone system (11) . It plays a role in the regulation of salt and water balance through its vasodilating, natriuretic and diuretic actions. Circulating levels of ANP are elevated when intravascular volume or right atrial pressure is increased (12) . Saline infusion has been shown to increase circulating ANP levels in healthy subjects (13) . Infusion of clonidine, an a 2 -adrenergic agonist, has also been shown to produce a marked increase in plasma ANP levels in healthy subjects (14) .
A correlation between female reproductive function and CGRP and ANP secretion has been postulated. Typical modifications of cardiovascular activity and salt and water balance homoeostasis throughout female reproductive life are well known (15) . In particular, menopause is associated with critical changes in the cardiovascular system, and the effect of hormonal replacement treatment (HRT) on these changes is under investigation (16, 17) .
Basal plasma CGRP levels in postmenopausal women are lower than in fertile women, and the assumption of an upright position is not associated with increased levels of plasma CGRP (18) . Increased plasma ANP levels have been found in postmenopausal women even though these changes have been related to age rather than to postmenopausal modifications (19) .
The aim of our study was to evaluate in postmenopausal women the effect of short-term HRT or a neuroendocrine drug (clonidine) on the response of (1) plasma CGRP levels to the upright posture test and (2) plasma ANP levels to the saline infusion test.
Materials and methods

Subjects
The present observational study included postmenopausal women (n=18; age range 46-53 years), who had been postmenopausal for at least 1 year and no longer than 5 years (follicle-stimulating hormone >30 mIU/ml, luteinizing hormone >20 mIU/ml, estradiol <25 pg/ml); all reported climacteric symptoms (hot flushes, anxiety). A group of them (n=13) was studied before and after two different HRT protocols (combined sequential schemes) for 3 months: five received estradiol valerate (2 mg/day for 21 days) in combination with cyproterone acetate (1 mg/day for the last 10 days) (Climen; Schering, Berlin, Germany) (HRT1), and eight were on a continuous-sequential scheme of transdermal estradiol-17b (50 mg/day for 28 days) (Dermestril TTS 50; Rottapharm, Monza, Italy) in combination with medroxyprogesterone acetate (10 mg/day for 14 days) (Farlutal; Farmitalia, Milano, Italy) (HRT2). Another group of women (n=5) was studied before and after 3 months of treatment with clonidine (0.15 mg/day) (Catapresan; Boehringer Ingelheim, Milano, Italy).
Before the study, a medical history was taken, and physical examination and routine laboratory tests were performed on each subject, which disclosed no abnormalities. Women with a history of gynecological cancer were excluded. None of the subjects smoked or had taken medication for the previous 3 months, except for HRT and clonidine in the specified groups. Informed consent was obtained from each subject after full description of the protocol, which had been approved by the local ethical committee.
Protocol
Patients were on a normosodic-normopotassic diet before the test and had fasted since the evening before the test. On separate days the tests were randomly carried out both before and after 3 months of HRT or clonidine treatment.
The effect of upright posture on plasma CGRP levels was evaluated after 2 h of bed rest between 0800 and 1000 h. Patients then assumed and maintained an upright position for the following 20 min, and blood specimens were collected, using i.v. cannulas in the antecubital veins, at 2, 5, 10 and 30 min.
The saline infusion test was carried out after 1 h of bed rest. During the infusion of saline (isotonic 150 mmol/l NaCl; 1250 ml in 2 h), blood samples were taken at 30, 60, 90, 120 and 180 min. The samples were collected in chilled tubes containing EDTA and 200 KIU of aprotinin/ ml (Trasylol; Bayer, Basel, Switzerland) and immediately centrifuged at 4 ЊC for 15 min at 1500 g. Plasma was separated, 200 KIU aprotinin/ml was added and the plasma stored in polystyrene tubes at ¹20 ЊC until extraction and assay. Heart rate and blood pressure were assessed each time blood specimens were collected. Manual sphygmomanometers were used in both tests.
CGRP assay
All reagents for the CGRP assay were purchased from Peninsula Laboratories (Belmont, CA, USA). The peptide was extracted from plasma specimens, acidified by adding 2 ml 0.1% trifluoroacetic acid and then centrifuged at 3000 g for 15 min at 4 ЊC. Solutions were applied to a Sep column (Waters, Rochester, USA) containing 200 mg C 18 previously activated by washing with 60% acetonitrile in 0.1% trifluoroacetic acid into a polypropylene tube. Mean recovery was 73%. The fractions collected were freeze-dried, redissolved in 0.5 ml phosphate buffer (pH 7.4) and submitted to RIA. Synthetic human (h)CGRP(1-37) standard or 0.1 ml reconstituted samples were incubated with 0.1 ml rabbit anti-hCGRP serum and 0·1 ml 125 I-TyrhCGRP in a total volume of 0.5 ml RIA buffer. After incubation for 12 h at 4 ЊC, 0.1 ml goat anti-rabbit immunoglobulin serum and 0.1 ml normal rabbit serum were added. The tubes were incubated for 6 h at 4 ЊC and centrifuged at 1700 g for 20 min at 4 ЊC. The supernatants were aspirated and the precipitates counted for radioactivity in a g-counter. Assay sensitivity was 0.4 fmol/assay tube and the 50% inhibitory dose was 8 fmol. The minimum amount of immunoreactive CGRP that could be detected in 1 ml plasma was less than 1 pmol/l. The intra-assay and interassay variabilities were 6 and 10% respectively. There was no interference with the assay from human calcitonin, human amylin, rat amylin amide and substance P. The cross-reactivity of the antiserum is, on a molar basis, 100% with hCGRP, hCGRP II, rat CGRP and rat CGRP II. Recovery was assessed using increasing amounts of standard hCGRP, and an 85% recovery was found (20) .
ANP assay
ANP was measured using reagents purchased from Immuno Technology Service Production BV (Wijchen, The Netherlands).
For ANP extraction, 1 ml plasma was acidified with 1.5 ml 4% acetic acid, run slowly through a Sep-Pak C 18 cartridge, washed twice with 3 ml distilled water, and eluted with 3 ml acetic acid in 86% ethanol. The samples were evaporated under a stream of nitrogen for 1 h at 37 ЊC; 1 ml 100% ethanol was then added, and the resulting solution mixed and evaporated to dryness. The residue was dissolved in 250 ml assay buffer (0.2 mol/l borate buffer+0.2% BSA in 30 ml) for 18 h at 4 ЊC. Then 200 ml 125 I-ANP tracer were added to the samples and incubated overnight at 4 ЊC. Bound and free ANP were separated by the addition of 1 ml precipitating reagent (horse anti-sheep immunoglobulin serum), incubated for 30 min at room temperature, centrifuged for 30 min at 2000 g, and the precipitate was counted in a g-counter. The intra-assay and interassay coefficients of variation were 8.6 and 11.6% respectively and the sensitivity was 2.3 pg/ml (20) .
Statistical analysis
Statistical analysis was performed with a Macintosh personal computer using the Abacus Concepts, StatView 4.0 program. All results are reported as the meanϮS.E.M. Related measures ANOVA was used for comparison of hormone levels between times, and the Scheffe F-test was used to determine the location of significant differences in mean values. Figure 1 shows that in postmenopausal women 3 months of HRT (HRT1 and HRT2) or clonidine treatment induces a significant increase in plasma CGRP levels (from 9.6Ϯ0.7 and 9.9Ϯ0.4 pmol/l to 13.8Ϯ1.6 and 14.1Ϯ1.6 pmol/l after HRT1 and HRT2 respectively; and from 10.5Ϯ1.6 pmol/l before clonidine treatment to 15.9Ϯ3.8 pmol/l after) (P<0.01). Whereas before the treatment the assumption of an upright posture was associated with no significant change in plasma CGRP, after both HRT protocols a significant increase in plasma CGRP levels was observed (from 13.8Ϯ1.6 and 14.1Ϯ1.6 pmol/l at time 0 to 30.8Ϯ1.3 and 29.9Ϯ1.9 pmol/l after 5 min) (P<0.01) (Fig. 2) . Patients under clonidine treatment did not show any significant response of plasma CGRP levels to upright posture (15.9Ϯ3.8 pmol/l at time 0 and 18.5Ϯ3.6 pmol/ after 2 min) (Fig. 2) .
Results
In the same patients, after both HRT and treatment with clonidine, plasma ANP levels significantly decreased (from 13.6Ϯ1.7 and 12.6Ϯ1.5 pmol/l to 5.8Ϯ1.1 and 6.2Ϯ1.7 pmol/l after HRT1 and HRT2 respectively; and from 11.7Ϯ5.3 pmol/l before clonidine to 6.0Ϯ2.6 pmol/l after) (P<0.01) (Fig. 1) . Before the start of treatment the saline infusion test did not induce any significant changes in plasma ANP levels (Fig. 3) . In patients on both HRT regimes a significant increase in plasma ANP levels during the saline infusion test (from 5.8Ϯ1.1 and 6.2Ϯ1.7 pmol/l at time 0 to 16.2Ϯ1.8 and 15.8Ϯ2.1 pmol/l after 90 min) (P<0.01) was observed, while no significant changes after clonidine treatment were detected (6.0Ϯ2.6 pmol/ l at time 0 and 8.5Ϯ3.1 pmol/l after 180 min) (Fig. 3) . Mean heart rate showed no significant change after HRT (74Ϯ6 vs 73Ϯ10 beats/min) or clonidine treatment (71Ϯ6 vs 70Ϯ9 beats/min). Mean heart rate also remained unmodified during the adaptive tests. On the other hand, mean blood pressure was reduced in patients after clonidine treatment (132Ϯ8 and 85Ϯ5 mmHg vs 113Ϯ10 and 78Ϯ2 mmHg) (P<0.01) and but not after HRT treatment (123Ϯ10 and 81Ϯ4 mmHg vs 125Ϯ10 and 79Ϯ6 mmHg), while it did not vary during the upright posture and saline infusion tests.
Discussion
The present study confirms that CGRP and ANP secretion is modified in postmenopausal women and shows that both HRT and clonidine treatment may affect their plasma levels. In fact, both treatments induce a significant increase in CGRP and a decrease in ANP plasma levels, suggesting that estrogen and/or adrenergic activity variations may modulate the mechanisms of secretion of both peptides in postmenopausal women. However, when CGRP and ANP secretion was evaluated under dynamic stimuli, only HRT showed a significant effect in restoring the functional response. With regard to the effect of HRT on plasma CGRP levels, the present data confirm our previous observation that plasma CGRP levels in climacteric women are significantly lower than in fertile controls and that 3 months of HRT restores CGRP plasma levels to control values (18) . Over the last decade a great effort has been exerted to clarify the mechanisms by which sex steroids affect the cardiovascular system. Our present findings are consistent with the hypothesis that cardiovascular hormone secretion is a possible target of HRT. In fact, estrogens have been shown to modulate the release and activity of some vasoactive substances in men and women (21) (22) (23) . In postmenopausal women HRT decreases plasma endothelin-1 levels (24) and is associated with higher serum levels of nitrite and nitrate, indicators of vascular nitric oxide release, than in untreated controls (25) . Moreover studies conducted in vitro have shown that prostacyclin release from endothelial cells is enhanced by estradiol17b (21) . The mechanism by which estrogen/progestins modulate CGRP and ANP secretion are not yet clearly understood. Immunocytochemical findings have shown that estrogen receptors are present in neurons producing CGRP in rat brain, and that estrogen treatment increases immunoreactive CGRP in rat pituitary (26) . In addition, estradiol-17b has been shown to stimulate CGRP expression in dorsal root ganglia of adult female Sprague-Dawley rats (27) . The effect of estrogens on ANP appears to be quite complex. The finding of an HRT-induced decrease in ANP plasma levels is apparently in contrast with the rise in ANP levels induced by oral contraceptives containing ethinyl estradiol in fertile women. Increased plasma ANP levels are described in some hyperestrogenic conditions, such as pregnancy (28) and in women taking hormonal contraceptives (29) . Since plasma ANP levels increase with age in both sexes (19, 30) , the increase in plasma ANP levels in postmenopausal women has been hypothesized to be a function of age and not of a physiological hormonal change at menopause (19) . In particular, the increase in ANP may be due to an age-related reduction in hemodynamic responsiveness to ANP (31) . In fertile women, high levels of estrogens augment reninangiotensin-aldosterone system activity, which in turn determines a rise in ANP secretion. In contrast, HRT with transdermal estradiol-17b or estradiol valerate after the menopause restores, at least partially, the premenopausal hormonal secretion, thus causing a reduction in ANP levels. The present longitudinal study primarily evaluates the effect of HRT on ANP levels in postmenopausal women. A previous cross-sectional study found no significant effect of HRT on ANP plasma levels (29) . However, different drugs and doses were used (0.625 mg conjugated equine estrogens on day 1 to 25 of each month and 10 mg medroxyprogesterone acetate was added on day 16 to 25).
In the present study, a 3 month treatment with clonidine provoked an increase in circulating levels of CGRP and a decrease in circulating levels of ANP in postmenopausal women, restoring the menopausal concentration range of both CGRP and ANP and reproducing the effect of HRT on these peptides. Clonidine treatment has been chosen to evaluate the effects of the modulation of the central adrenergic tone, via a 2 -adrenergic receptor stimulation, on CGRP and ANP levels. Various pieces of evidence for the involvement of a 2 -adrenergic receptors in the regulation of the release of vasoactive peptides have been reported. CGRP-containing vasodilator nerves of rat mesenteric vessels are inhibited by norepinephrine, through the activation of a 2 -adrenoceptors (32). On the other hand, infusion of clonidine in conscious rats (33) and humans (14) produces a marked increase in plasma ANP levels. The apparent contrast between these data and our results on the effects of clonidine on ANP levels is possibly due to the different means of administration of the drug: acute infusion compared with long-term oral clonidine.
A major observation of our study is that, in postmenopausal women, the physiological response of CGRP and ANP to the assumption of upright posture and to saline infusion is restored after HRT but not after clonidine treatment. During the climacteric period, the progressive decline in ovarian steroid release results in modifications of the responses to adaptive stimuli. This reflects numerous differences in neuroendocrine activity, involving modifications of neuronal connections, pituitary hormone levels and neurohormonal systems. Our present observations suggest that the neuroactive peptides involved in the control of blood pressure and water homoeostasis are part of those neuroendocrine pathways that are affected by the menopause. The administration of estrogens, or of steroids with estrogenic properties, restores these neurotransmitting systems. In fact, estrogens modify serotoninergic, dopaminergic and adrenergic tone in rat brain (34, 35) . However, studies of the response of CGRP and ANP to adaptive stimuli during the menstrual cycle are necessary to understand more fully the role of estrogen levels on these vasoactive peptides.
In contrast with HRT, clonidine treatment does not restore CGRP and ANP responses to upright posture and saline infusion respectively. A possible explanation is that the effect of estrogens on the response of vasoactive peptides to adaptive stimuli involves mechanisms other than the modulation of adrenergic tone, as determined by clonidine.
In conclusion, the present results show that some of the adaptive responses modified by menopausal changes are restored under HRT but not under clonidine treatment. Sex steroid hormones play a modulatory role in the regulation of CGRP and ANP secretion in postmenopausal women and the regulation of these vasoactive peptides by estrogens or clonidine occurs via different mechanisms.
